Martin A. Bast

University of Nebraska Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Dennis D. Weisenburger

University of Nebraska Medical Center

Julie M. Vose

University of Nebraska Medical Center

Philip J. Bierman

University of Nebraska at Omaha

Robert Bagin

Verus Research (United States)

J. O. Armitage

University of Nebraska Medical Center

James O. Armitage

Palmetto Hematology Oncology

Hirokazu Nakamine

Baptist Hospital

Deborah Perry

Methodist Hospital

Cooperative Institutions

University of Nebraska Medical Center

Nebraska Medical Center

University of Nebraska at Omaha

Fred and Pamela Buffett Cancer Center

Susan Thompson Buffett Foundation

Memorial Sloan Kettering Cancer Center

Palmetto Hematology Oncology

Society of Surgical Oncology

Brunswick (United States)

City of Hope

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma

Cancer (1990)

Deborah Perry Martin A. Bast James O. Armitage Dennis D. Weisenburger

Controversy has recently arisen as to whether diffuse intermediate lymphocytic lymphoma (ILL) should be considered a low-grade or an intermediate-grade non-Hodgkin's lymphoma for clinical purposes. Therefore, the authors performed a clinicopathologic study to determine the biologic course of diffuse ILL (40 cases) and compared it with small lymphocytic lymphoma (SLL; 51 cases) and diffuse small cleaved cell lymphoma (DSCCL; 14 cases). They found that patients with diffuse ILL having pseudofollicular proliferation centers (PC) had a significantly longer median survival (84 months) than those without PC (46.5 months; P = 0.03). The median survival of patients with SLL was 72 months, whereas those with DSCCL had a median survival of only 18 months. Based on these findings, the authors conclude that diffuse ILL with PC should be included in the low-grade category of SLL for clinical purposes, whereas diffuse ILL without PC (true diffuse ILL) should be considered an intermediate-grade non-Hodgkin's lymphoma. True diffuse ILL is similar to centrocytic lymphoma in the Kiel classification and should be accorded a similar status in a modified Working Formulation.

10.1002/1097-0142(19901101)66:9<1995::aid-cncr2820660925>3.0.co;2-q

Cite

Citations (44)

Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma

Cancer (1993)

Hirokazu Nakamine Dennis D. Weisenburger Robert Bagin Julie M. Vose Martin A. Bast

The diffuse large cell non-Hodgkin lymphomas are a heterogeneous group of neoplasms that are potentially curable. To identify important predictors of clinical outcome, the authors evaluated the clinical and pathologic features of 114 patients with newly diagnosed diffuse large B-cell lymphoma who were uniformly staged and treated with curative intent. The authors were particularly interested in determining whether any pathologic features added to the ability of the clinical features to predict patient survival.Several clinical and pathologic features were found to be associated with survival by univariate analysis. However, multivariate analysis disclosed that only the stage of disease and the symptom status were significantly associated with survival. Low stage and lack of B symptoms were favorable indicators of overall survival and failure-free survival.The authors suggest that the evaluation of pathologic features in diffuse large B-cell lymphoma has little prognostic utility and recommend that the pathology evaluation be limited to features that are useful for diagnostic purposes.

Univariate analysis

Large-cell lymphoma

B symptoms

Univariate

10.1002/1097-0142(19930515)71:10<3130::aid-cncr2820711039>3.0.co;2-r

Cite

Citations (18)